Comparative Pharmacology
Head-to-head clinical analysis: KAON CL versus MICRO K 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAON CL versus MICRO K 10.
KAON CL vs MICRO-K 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium supplement; replaces potassium ions lost due to potassium-wasting diuretics or other conditions, maintaining intracellular and extracellular potassium balance essential for nerve conduction, muscle contraction, and acid-base homeostasis.
Potassium is the major intracellular cation; it is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Potassium chloride is absorbed from the gastrointestinal tract and distributes throughout the body. The microencapsulated formulation allows for gradual release of potassium, minimizing gastrointestinal irritation.
Oral: 20 mEq (one tablet) two to four times daily with meals and a full glass of water; maximum 100 mEq/day. Slow-release tablet should not be crushed or chewed. Intravenous: not applicable for KAON CL (oral formulation).
10 mEq (2 capsules) orally once daily, or 20 mEq (2 capsules) twice daily, or as directed by physician. Maximum 100 mEq/day.
None Documented
None Documented
Terminal half-life is approximately 0.5–1.5 hours in healthy individuals; prolonged in renal impairment (up to 6–12 hours in end-stage renal disease).
Not applicable; potassium is not cleared by first-order kinetics. Whole-body potassium turnover half-life is approximately 30 days, but this is not clinically relevant for supplementation.
Primarily renal: >90% excreted unchanged in urine; minimal biliary/fecal elimination (<5%).
Primarily renal: 90% of absorbed potassium is excreted in urine as potassium ions; 10% eliminated in feces via biliary and intestinal secretion.
Category C
Category C
Electrolyte Supplement (Potassium)
Electrolyte Supplement (Potassium)